Placebo (sitagliptin)

DRUG2 trials

Sponsors

Boehringer Ingelheim, Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2

Phase 2

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

CompletedNCT00716092

Boehringer IngelheimDiabetes Mellitus, Type 2

Start: 2008-07-31Updated: 2014-06-27

Phase 3

A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

CompletedNCT04017832

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2019-07-29End: 2021-10-27Updated: 2024-10-01

Related Papers

Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial

Diabetologia2024-07-1017 citations

Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial.

2024-07-1013 citations